MediciNova Inc

MNOV NASDAQ
9.19
+0.35
+3.96%
Opening 14:43 08/21 EDT
Open
8.95
Prev Close
8.84
High
9.22
Low
8.95
Volume
58.84K
Avg Vol (3M)
122.90K
52 Week High
13.37
52 Week Low
6.68
% Turnover
0.14%
Market Cap
397.46M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers MediciNova Inc MNOV stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Medicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin). MN-166 is an oral, anti-inflammatory and neuroprotective agent. MN-166 is in development for the treatment of several neurological diseases, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance dependence and addiction. MN-001 (tipelukast) is an orally bioavailable small molecule compound, which is used for the treatment of fibrotic diseases, such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. MN-221 treats acute exacerbations of asthma through intravenous infusion, bypassing constricted airways to deliver the drug to the lungs. MN-029 is used for the treatment of solid tumor cancers.
MORE >

Recently

Name
Price
%Change